Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Inhalant, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Bosnia | Bulgaria | Canada | Chile | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AZIENDA OSPEDALIERA MEYER
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, United Kingdom
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pneumonia, Ventilator-Associated|Shock, Septic|Urinary Tract Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20221991 |
CTR20221991 | P3 |
Completed |
Pneumonia, Ventilator-Associated|Urinary Tract Infections |
2025-06-25 |
2025-11-09 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT02389036 |
SuDDICU | P3 |
Completed |
Pneumonia, Ventilator-Associated|Shock, Septic |
2023-04-26 |
2024-11-27 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/11/2025 |
News Article |
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update |
|
10/15/2025 |
News Article |
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund |
|
08/07/2025 |
News Article |
Poultry Antibiotic Market Poised for Growth, Expected to Hit USD 3.38 Billion by 2032 -Coherent Market Insights |
|
02/07/2025 |
News Article |
U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options |